Home
Clinical Trials
Efficacy and Safety Study of ...

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

Last Updated: 2017-02-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

758 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2016-09-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Purpose of this trial:

1. To assess the efficacy and safety of NeuVax™ administered with adjuvant Leukine® (sargramostim, GM-CSF).
2. To evaluate and compare the disease free survival (DFS) in the vaccinated and control subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients

NCT02297698

Breast Cancer

COMPLETED PHASE2

Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients

NCT06845319

Triple Negative Breast Cancer

RECRUITING PHASE2

HER2-Peptide Vaccination of Patients With Solid Tumors

NCT02276300

Gastric Cancer Breast Cancer

COMPLETED PHASE1

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

NCT03606967

Anatomic Stage IV Breast Cancer AJCC v8 Invasive Breast Carcinoma Metastatic Triple-Negative Breast Carcinoma

RECRUITING PHASE2

Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer

NCT04418219

Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8 +2 more

WITHDRAWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter, multinational, prospective, randomized, double-blind, controlled Phase 3 study.

The subjects eligible for this trial have an early stage node-positive breast cancer. Their tumors express low or intermediate levels of the HER2 protein. NeuVax™ will be administered after completion of front-line, standard of care therapy (surgery, radiation therapy, and chemotherapy) and can be given concomitantly with physician prescribed endocrine treatment.

NeuVax™ is the immmunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a well-established target for therapeutic intervention in breast carcinoma. The nelipepimut sequence stimulates specific CD8+ cytotoxic T lymphocytes (CTL) following binding to HLA-A2/A3 molecules on antigen presenting cells (APC). These activated specific CTLs recognize, neutralize and destroy through cell lysis HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading. Based on a successful Phase 2 trial, which achieved its primary endpoint of DFS, the Food and Drug Administration (FDA) granted NeuVax a Special Protocol Assessment (SPA) for its Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study.

The active portion of the study will last three years (36 months). The follow-up will last from 5 to 10 years.

Endpoints:

1. Primary efficacy endpoint:

* 3-year DFS
2. Secondary efficacy endpoints:

* 5- and 10-year DFS
* 3-year OS
* 5- and 10-year OS
* Safety profile, and adverse events (AEs)
* Patterns of recurrence to include Time to recurrence (TTR), time to local recurrence (TTLR), time to distant recurrence (TTDR), time to bone metastases (TTBM)

Safety Assessments:

Subjects will be assessed at every study visit for the safety endpoints, AEs,vital signs, physical examinations and laboratory data; yearly follow-up of survival will include imaging studies, ECGs, MUGA or ECHO scans and concomitant medications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer With Low to Intermediate HER2 Expression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NeuVax™

NeuVax™ in WFI solution with Leukine®

Group Type EXPERIMENTAL

NeuVax™ vaccine

Intervention Type BIOLOGICAL

E75 peptide acetate (HER2/neu p366-379) in WFI (1.5 mg/mL) mixed with 250 micrograms Leukine® (sargramostim, GM-CSF), will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, NeuVax™ vaccine boosters will be given the same way once every six months for the next five times (totaling 36 months).

Leukine®

Leukine® with WFI

Group Type ACTIVE_COMPARATOR

Leukine® (sargramostim, GM-CSF) and water for injection

Intervention Type BIOLOGICAL

Leukine® 250 micrograms in water for injection, will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, boosters inoculations will be given the same way once every six months for the next five times (totaling 36 months).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NeuVax™ vaccine

Intervention Type BIOLOGICAL

Leukine® (sargramostim, GM-CSF) and water for injection

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

E75 peptide acetate , WFI, sargramostim, GM-CSF Leukine®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pathological diagnosis of invasive adenocarcinoma of the breast
* Breast cancer completely excised, or patient receiving neoadjuvant therapy prior to surgery
* One of these 2 surgical treatments and axillary staging with sentinel lymph node dissection or axillary dissection level I/II:

1. Total mastectomy-patients with a positive sentinel lymph node must have undergone a completion axillary dissection level I/II
2. BCS (lumpectomy)-patients with a positive sentinel lymph node must have undergone a completion axillary dissection level I/II unless they had clinically node negative T1-T2 tumors and fewer than 3 involved lymph nodes
* Node-positive disease
* Primary tumor stage T1-3 at initial diagnosis
* HER2 negative (HER2 1+ by IHC or HER2 2+ by IHC/FISH)
* HLA-A2 or HLA-A3 haplotype
* Completed NCCN approved neo-adjuvant/adjuvant chemotherapy or both
* Completed radiation therapy
* No evidence of disease
* Able and willing (or have legal representative) to understand the study and provide consent

Exclusion Criteria

* Bilateral breast malignancy or suspicious mass in opposite breast
* Inflammatory breast malignancy
* History of prior breast cancer, ductal carcinoma in situ
* Prior trastuzumab therapy
* New York Heart Association Stage 3 or 4 cardiac disease
* Sensory/motor neuropathy ≥ Grade 2
* Autoimmune diseases or immune deficiency disease
* Subjects on chronic steroid therapy, other immunosuppressive therapy

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Elizabeth A Mittendorf, MD,FACS

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alabama Oncology

Bessemer, Alabama, United States

Site Status

Physicians Pain Specialists of Alabama, P.C.

Mobile, Alabama, United States

Site Status

Pain Centers Nationwide

Peoria, Arizona, United States

Site Status

Valley Pain Consultants

Scottsdale, Arizona, United States

Site Status

East Valley Hematology and Oncology Medical Group

Burbank, California, United States

Site Status

Coastal Pain Research

Carlsbad, California, United States

Site Status

Navajo Road Pain Management Center

El Cajon, California, United States

Site Status

California Cancer Associates for Research and Excellence, Inc.

Fresno, California, United States

Site Status

California Cancer Associates For Research and Excellence

Fresno, California, United States

Site Status

St. Jude Medical Center, Virginia K. Crosson Cancer Center

Fullerton, California, United States

Site Status

Interventional Pain Management

Irvine, California, United States

Site Status